Fujimoto Pharmaceutical Corp. has identified dioxopiperidine derivatives reported to be useful for the treatment of cancer.

Shenzhen Bay Laboratory has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of Parkinson’s disease, epilepsy, pain, depression, schizophrenia, substance abuse and dependence, post-traumatic stress and autism spectrum disorders.

Valo Health Inc. has disclosed sphingosine 1-phosphate receptor 1 (S1P1 receptor; EDG1) agonists reported to be useful for the treatment of multiple sclerosis, psoriasis, amyotrophic lateral sclerosis, systemic lupus erythematosus, ulcerative colitis, lymphopenia and Crohn’s disease.

Pfizer Inc. has described nucleoprotein N (respiratory syncytial virus [RSV]) inhibitors reported to be useful for the treatment of RSV infection.

University of Maryland has divulged pyrazinamide (PZA)-mimicking prodrugs reported to be useful for the treatment of tuberculosis.

Institut National Supérieur des Sciences Agronomiques de l’Alimentation et de l'Environnement has identified compounds reported to be useful for the treatment of cryptosporidiosis. 

Shemyakin Institute of Bioorganic Chemistry has synthesized perylenylethynylphenol derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Sunshine Lake Pharma Co. Ltd. has disclosed Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.

Bristol Myers Squibb Co. has identified new GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, Huntington’s disease, Parkinson’s disease, psychosis and drug abuse and dependence.